BMO lifts Protagonist Therapeutics price target to $190
BMO Capital raised its Protagonist Therapeutics price target to $190.00 per share from $178.00 and maintained an Outperform rating, per Benzinga/TradingView.
Ratings actions GMT) Protagonist Therapeutics Price Target Raised to $190.00/Share From $178.00 by BMO CapitalRatings actions